WALLSTENT TRANSHEPATIC BILIARY ENDOPROSTHESIS

K982005 · Boston Scientific Scimed, Inc. · FGE · Sep 2, 1998 · Gastroenterology, Urology

Device Facts

Record IDK982005
Device NameWALLSTENT TRANSHEPATIC BILIARY ENDOPROSTHESIS
ApplicantBoston Scientific Scimed, Inc.
Product CodeFGE · Gastroenterology, Urology
Decision DateSep 2, 1998
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 876.5010
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Schneider WALLSTENT® Biliary Endoprosthesis is indicated for use in the treatment of biliary strictures produced by malignant neoplasms.

Device Story

Self-expanding biliary stent; constructed of biomedical superalloy and elastomeric polymer; braided wire structure. Stent increases/maintains inner lumen diameter of biliary duct. Delivered via coaxial tubing assembly; outer sheath retraction releases stent. Modified Unistep™ Plus delivery system allows partial deployment and reconstrainment for precise placement. Sterile; single-use. Used by clinicians for biliary intervention.

Clinical Evidence

Bench testing only. In vitro and in vivo deployment testing performed to compare deployment forces and handling characteristics of the modified delivery system against predicate systems.

Technological Characteristics

Self-expanding braided wire stent; materials: biomedical superalloy and elastomeric polymer. Delivery system: coaxial tubing assembly. Modified delivery system allows partial deployment and reconstrainment. Sterile, single-use.

Indications for Use

Indicated for treatment of biliary strictures caused by malignant neoplasms.

Regulatory Classification

Identification

A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.

Special Controls

*Classification.* Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ #### 2 1998 SEP | 16. 510(k) Summary | |--------------------| |--------------------| | Date Prepared | June 4, 1998 | |----------------|------------------------------------------------------------------| | Submitter | | | Address: | Schneider (USA) Inc<br>5905 Nathan Lane<br>Minneapolis, MN 55442 | | Phone : | (612) 550-5500 | | Fax : | (612) 550-5771 | | Contact Person | Ronald W. Bennett<br>Senior Regulatory Affairs Specialist | | Device Name and Classification | | |--------------------------------|--| |--------------------------------|--| | Trade Name | WALLSTENT® Biliary Transhepatic<br>Endoprosthesis with Unistep™ Plus Delivery<br>System | |-------------------|---------------------------------------------------------------------------------------------------------------------| | Common Name | Biliary Stent | | Classification | Class II | | Predicate Devices | WALLSTENT® Biliary Transhepatic<br>Endoprosthesis with Unistep™ Plus Delivery<br>System - K923993, K961262, K964119 | # Device Description The WALLSTENT® Biliary Endoprosthesis is a self-expanding prosthesis constructed of biomedical superalloy and an elastomeric polymer. The prosthesis is a braided wire structure. The outward radial force along with the ends of the device serve to stabilize the prosthesis after implanted. The stent's purpose is to increase or maintain the inner lumen diameter of the biliary duct. The stent is placed by means of a delivery system. The delivery system is a coaxial tubing assembly that constrains the prosthesis until it is released in a controlled manner. The release of the stent is accomplished by retracting the outer sheath. The prosthesis is packaged constrained on the delivery system ready for placement. The system is sterile and intended for single use only. {1}------------------------------------------------ ### Indication The WALLSTENT® Biliary Endoprosthesis is intended for use in the treatment of biliary strictures produced by malignant neoplasms. 1982005 # Technological Characteristics The purpose of this 510(k) is to allow an alternate delivery system. Compared to the Unistep™ Delivery System (K961262, K923993), the Unistep™ Plus delivery system allows the user to partially deploy and then reconstrain the stent to facilitate placement. Compared to the present Unistep™ Plus Delivery System (K964119), the modified system has different materials for the outer and inner tubing. This feature is presently available for the 12 mm stent with the change in materials in the WALLSTENT® Tracheobronchial Endoprosthesis with Unistep™ Plus Delivery System (K980163). The alternate delivery system can be found substantially equivalent based on the results of in vitro and in vivo deployment testing which demonstrate that deployment forces and handling characteristics are comparable to the current delivery systems. ## Summary In summary Schneider (USA) Inc has demonstrated that the WALLSTENT® Biliary Endoprosthesis with Unister ™ Plus Delivery System with modified delivery system is substantially equivalent based on design, test results, and indications for use to the predicate devices. {2}------------------------------------------------ Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes representing the department's mission. The text "DEPARTMENT OF HEALTH & HUM." is arranged in a semi-circle around the left side of the eagle, and the text "SERVICES - USA" is arranged in a semi-circle around the right side of the eagle. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 2 1998 SEP Mr. Ronald W. Bennett Senior Regulatory Affairs Specialist Schneider (USA) Inc. Pfizer Medical Technology Group 5905 Nathan Lane Minneapolis, MN 55442 Re: K982005 WALLSTENT® with Unistep™ Plus (Biliary Stent and Catheter) Dated: June 4, 1998 Received: June 8, 1998 Regulatory Class: II 21 CFR 876.5010/Procode: 78 FGE Dear Mr. Bennett: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/odrh/dsmaldsmamain.html". Sincerely yours Lillian Yin, Ph.D. Director, Division of Reproducti Abdominal, Ear, Nose and Throat and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ Page _________________________________________________________________________________________________________________________________________________________________________ 510(k) Number (if known): Schneider WALLSTENT® Biliary Endoprosthesis Device Name: Indications for Use: The Schneider WALLSTENT® Biliary Endoprosthesis is indicated for use in the treatment of biliary strictures produced by malignant neoplasms. PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use (Per 21 CFR 801.109) OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (Optional Format 1-2-96) David G. Severson (Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Deyi 510(k) Number
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...